Abstract
Motor impairment, especially ataxia, is often mentioned as a 'side effect' of doses of psychoactive drugs which depress animal behaviour; it is difficult to determine it accurately from visual observation, but relatively few attempts have been made to measure it objectively and quantitatively. Mescaline, in moderate to large doses, can induce biphasic--depressant followed by stimulant--effects on learnt and other performance of laboratory rodents. Motor impairment, using three doses, was accordingly measured during the depressant phase by two methods. An 'ataxia' test, involving analyses of footprints, showed few irregularities of gait splay due to mescaline, but the drug markedly reduced the length of steps ('stride') in a dose-related manner. In a 'tilt plane' test for general motor control, the animals' ability to cling to a tilted plane decreased with 25 mg/kg mescaline, at 30 and 40 minutes after administration. Deficits of this kind can be relevant to interpreting drug actions on forms of behaviour which involve movements for responding, and they also have interesting potential in their own right.
References
Sep 1, 1979·Psychopharmacology·M A GeyerR L Hawkins
Apr 29, 1977·Psychopharmacology·D A Gorelick, W H Bridger
Jul 9, 1979·Life Sciences·R E HruskaE K Silbergeld
Jan 1, 1979·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·A Delini-StulaP R Hedwall
Mar 31, 1978·Science·T SchallertP Teitelbaum
Sep 18, 1978·Life Sciences·W M BournJ F Bonfiglio
Oct 2, 1978·Life Sciences·H A Tilson, P A Cabe
Jul 28, 1976·Psychopharmacology·L R Northup
Jun 1, 1977·Toxicology and Applied Pharmacology·P M Edwards, V H Parker
Aug 1, 1975·Experimental Neurology·P MullenixB Culver
Sep 11, 1964·Psychopharmacologia·J R Smythies, E A Sykes
Nov 1, 1980·Acta Pharmacologica Et Toxicologica·S B Ross
Jan 1, 1984·Annual Review of Pharmacology and Toxicology·H A Tilson, C L Mitchell
Jan 1, 1981·Psychopharmacology·J L GibbonsW H Bridger
Jan 1, 1982·Pharmacology, Biochemistry, and Behavior·M L Elliott, R J Sbordone
Aug 29, 1959·Nature·H WALLGREN
Citations
Oct 9, 2007·Psychopharmacology·Tomás PálenícekJirí Horácek
Jul 31, 2012·Psychopharmacology·Tomáš PáleníčekCyril Höschl
Apr 1, 1989·Journal of Pharmacological Methods·H SteinbergH Tillotson
Feb 17, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomás PálenícekJirí Horácek
Jan 19, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Evan J KyzarAllan V Kalueff
Dec 21, 2010·Pharmacology, Biochemistry, and Behavior·Tomáš PáleníčekCyril Höschl
May 3, 2007·Rapid Communications in Mass Spectrometry : RCM·Jin Young KimMoon Kyo In
Jun 1, 2017·International Journal of Technology Assessment in Health Care·Esther JacobsMichaela Eikermann
May 21, 2015·Therapeutic Drug Monitoring·Dilek BattalMarilyn A Huestis
May 31, 2018·ACS Chemical Neuroscience·Bruce K Cassels, Patricio Sáez-Briones